ArticleOncotarget2018

Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.

Guillermo Montalban-Bravo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.